Zacks Investment Research Upgrades POXEL (PXXLF) to Buy

Zacks Investment Research upgraded shares of POXEL (OTCMKTS:PXXLF) from a hold rating to a buy rating in a research report released on Wednesday. Zacks Investment Research currently has $6.00 price objective on the stock.

According to Zacks, “Poxel SA is a biopharmaceutical company. It offers drugs for metabolic diseases such as diabetes and related metabolic disorders. The company’s product pipeline consists of Imeglimin, PXL770 and PXL007 which are in clinical trial stage. Poxel SA is headquartered in Lyon, France. “

POXEL (PXXLF) opened at $5.35 on Wednesday.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Upgrades POXEL (PXXLF) to Buy” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.thestockobserver.com/2018/01/14/zacks-investment-research-upgrades-poxel-pxxlf-to-buy.html.

Get a free copy of the Zacks research report on POXEL (PXXLF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for POXEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POXEL and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply